ArticlePlastic and reconstructive surgery. Global open2026
Impact of COVID-19 Infection and Vaccination on Abdominal-based Microvascular Breast Reconstruction Outcomes.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SARS-CoV-2 (COVID-19) infection increases thrombotic risk; however, its impact on microsurgical breast reconstruction outcomes remains unclear. This study examines postoperative complications in patients following abdominal-based microvascular breast reconstruction relative to (1) timing relative to the COVID-19 pandemic, (2) history of COVID-19 infection, and (3) time since COVID-19 vaccination/booster. Methods: A retrospective review of patients who underwent abdominal-based microvascular breast reconstruction was conducted. Patients were categorized into pre-COVID-19 (January 23, 2017-January 19, 2020, n = 236) and post-COVID-19 (January 20, 2020-October 17, 2022, n = 233) groups. The post-COVID-19 group was further stratified by COVID-19 infection history and vaccination/booster status, within 40 days before surgery. Sociodemographic, clinical, and postoperative complication data were analyzed. Results: The sample included 469 patients with a median age of 50 years and mean body mass index of 28.6 kg/m Conclusions: Postoperative complication rates were similar between pre- and post-COVID-19 cohorts. COVID-19 infection or recent vaccination within 40 days before surgery was not associated with increased risk of major complications, including thrombotic events, in abdominal-based microvascular breast reconstruction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.